202 related articles for article (PubMed ID: 19188144)
1. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation.
Gerner EW; Meyskens FL
Clin Cancer Res; 2009 Feb; 15(3):758-61. PubMed ID: 19188144
[TBL] [Abstract][Full Text] [Related]
2. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
Rial NS; Meyskens FL; Gerner EW
Essays Biochem; 2009 Nov; 46():111-24. PubMed ID: 20095973
[TBL] [Abstract][Full Text] [Related]
3. Targeting polyamines and inflammation for cancer prevention.
Babbar N; Gerner EW
Recent Results Cancer Res; 2011; 188():49-64. PubMed ID: 21253788
[TBL] [Abstract][Full Text] [Related]
4. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
[TBL] [Abstract][Full Text] [Related]
5. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Martinez ME; O'Brien TG; Fultz KE; Babbar N; Yerushalmi H; Qu N; Guo Y; Boorman D; Einspahr J; Alberts DS; Gerner EW
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7859-64. PubMed ID: 12810952
[TBL] [Abstract][Full Text] [Related]
6. Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.
Gerner EW; Bruckheimer E; Cohen A
J Biol Chem; 2018 Nov; 293(48):18770-18778. PubMed ID: 30355737
[TBL] [Abstract][Full Text] [Related]
7. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models.
Gerner EW
Biochem Soc Trans; 2007 Apr; 35(Pt 2):322-5. PubMed ID: 17371270
[TBL] [Abstract][Full Text] [Related]
8. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
[TBL] [Abstract][Full Text] [Related]
9. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
11. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
12. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
13. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.
Erdman SH; Ignatenko NA; Powell MB; Blohm-Mangone KA; Holubec H; Guillén-Rodriguez JM; Gerner EW
Carcinogenesis; 1999 Sep; 20(9):1709-13. PubMed ID: 10469614
[TBL] [Abstract][Full Text] [Related]
14. Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.
Tuma R
J Natl Cancer Inst; 2008 Jun; 100(11):764-6. PubMed ID: 18505958
[No Abstract] [Full Text] [Related]
15. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
16. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
17. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of hereditary colon cancers: time for new strategies.
Ricciardiello L; Ahnen DJ; Lynch PM
Nat Rev Gastroenterol Hepatol; 2016 Jun; 13(6):352-61. PubMed ID: 27095653
[TBL] [Abstract][Full Text] [Related]
19. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
20. Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies.
Murray-Stewart T; Dunworth M; Lui Y; Giardiello FM; Woster PM; Casero RA
PLoS One; 2018; 13(8):e0202677. PubMed ID: 30138353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
